Jun Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4459136/publications.pdf

Version: 2024-02-01

57	5,801	19	55
papers	citations	h-index	g-index
61	61	61	9122
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China. European Journal of Clinical Pharmacology, 2022, 78, 215-225.	0.8	2
2	Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. Thrombosis Research, 2022, 209, 16-22.	0.8	1
3	Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. Platelets, 2022, 33, 900-910.	1.1	2
4	Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study. Cardiovascular Diabetology, 2022, 21, 48.	2.7	34
5	Relationship between creatinine clearance and clinical outcomes in Chinese emergency patients with atrial fibrillation. Annals of Noninvasive Electrocardiology, 2022, 27, e12942.	0.5	2
6	Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2022, 9, 756082.	1.1	0
7	Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 846803.	1.1	2
8	Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension. BMC Cardiovascular Disorders, 2022, 22, 141.	0.7	6
9	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	1.4	6
10	Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a i > post hoc < i > analysis of the ATHENA trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 363-371.	1.4	0
11	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal, 2022, 43, 3542-3552.	1.0	7
12	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovascular Research, 2021, 117, 942-949.	1.8	15
13	Type of atrial fibrillation and outcomes in patients without oral anticoagulants. Clinical Cardiology, 2021, 44, 168-175.	0.7	5
14	The use of intravenous amiodarone in patients with atrial fibrillation and Wolffâ€Parkinsonâ€White syndrome. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 35-43.	0.5	8
15	Elevated Plasma Big Endothelin-1 at Admission Is Associated With Poor Short-Term Outcomes in Patients With Acute Decompensated Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 629268.	1.1	8
16	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	1.0	18
17	A new scoring system for predicting shortâ€ŧerm outcomes in Chinese patients with criticallyâ€ill acute decompensated heart failure. BMC Cardiovascular Disorders, 2021, 21, 228.	0.7	2
18	The Characteristics, Long-Term Outcomes, Risk Factors, and Antithrombotic Therapy in Chinese Patients With Atrial Fibrillation and Bioprosthetic Valves. Frontiers in Cardiovascular Medicine, 2021, 8, 665124.	1.1	2

#	Article	IF	Citations
19	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	1.0	10
20	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1133-1146.	6.3	87
21	Performance of the REACH, PARIS, BleeMACS, and PRECISE-DAPT scores for predicting 1-year bleeding events in patients undergoing coronary drug-eluting stent implantation. Platelets, 2021, , 1-8.	1.1	1
22	Association between body mass index and mortality in atrial fibrillation patients with and without diabetes mellitus: Insights from a multicenter registry study in China. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2242-2251.	1.1	3
23	The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Platelets, 2020, 31, 971-980.	1.1	10
24	Genderâ€specific association between body mass index and allâ€cause mortality in patients with atrial fibrillation. Clinical Cardiology, 2020, 43, 706-714.	0.7	7
25	Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. Journal of Geriatric Cardiology, 2020, 17, 750-758.	0.2	0
26	Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China. BMC Cardiovascular Disorders, 2019, 19, 209.	0.7	10
27	Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF). Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	12
28	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology, 2018, 34, 38-44.	0.8	13
29	Self-Recognition of an Inducible Host IncRNA by RIG-I Feedback Restricts Innate Immune Response. Cell, 2018, 173, 906-919.e13.	13.5	224
30	The association between plasma big endothelin-1 levels at admission and long-term outcomes in patients with atrial fibrillation. Atherosclerosis, 2018, 272, 1-7.	0.4	12
31	Early Invasive Versus Initially Conservative Strategy in Elderly Patients Older Than 75 Years with Non-ST-Elevation Acute Coronary Syndrome: A Meta-Analysis. Heart Lung and Circulation, 2018, 27, 611-620.	0.2	7
32	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	6.3	651
33	Albumin-to-creatinine ratio as a predictor of all-cause mortality and hospitalization of congestive heart failure in Chinese elder hypertensive patients with high cardiovascular risks. Clinical Hypertension, 2018, 24, 12.	0.7	7
34	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health, 2017, 5, e665-e672.	2.9	247
35	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
36	Predictors of digoxin use and risk of mortality in ED patients with atrial fibrillation. American Journal of Emergency Medicine, 2017, 35, 1589-1594.	0.7	6

#	Article	IF	CITATIONS
37	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	13.9	1,7 45
38	Comparison of 4 Admission Blood Pressure Indexes for Predicting 30-Day Mortality in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Hypertension, 2016, 29, 332-339.	1.0	17
39	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
40	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	13.9	641
41	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
42	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. American Heart Journal, 2016, 178, 145-150.	1.2	52
43	Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. Atherosclerosis, 2016, 251, 305-310.	0.4	10
44	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. International Journal of Cardiology, 2016, 204, 133-141.	0.8	108
45	Serum Potassium Levels and Short-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. Angiology, 2016, 67, 729-736.	0.8	11
46	Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2016, 117, 926-934.	0.7	61
47	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	0.8	24
48	Clinical Characteristics and Impact of Diabetes Mellitus on Outcomes in Patients with Nonvalvular Atrial Fibrillation. Yonsei Medical Journal, 2015, 56, 62.	0.9	12
49	One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation. Angiology, 2015, 66, 745-752.	0.8	12
50	Impact of initial 24-hÂurine output on short-term outcomes in patients with ST-segment elevation myocardial infarction admitted without cardiogenic shock and renal dysfunction. Atherosclerosis, 2015, 240, 137-143.	0.4	1
51	Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clinical Interventions in Aging, 2014, 9, 1335.	1.3	9
52	Clinical characteristics and short-term outcomes in patients with elevated admission systolic blood pressure after acute ST-elevation myocardial infarction: a population-based study. BMJ Open, 2014, 4, e005097-e005097.	0.8	7
53	Low admission platelet counts predicts increased risk of in-hospital mortality in patients with type A acute aortic dissection. International Journal of Cardiology, 2014, 172, e484-e486.	0.8	45
54	Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: A national wide database analysis. International Journal of Cardiology, 2014, 173, 242-247.	0.8	21

#	Article	IF	CITATIONS
55	Usefulness of the Admission Shock Index for Predicting Short-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 114, 1315-1321.	0.7	51
56	Clinical Characteristics and Prognostic Significance of Chronic Obstructive Pulmonary Disease in Patients With Atrial Fibrillation: Results From a Multicenter Atrial Fibrillation Registry Study. Journal of the American Medical Directors Association, 2014, 15, 576-581.	1.2	39
57	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547